Dentsply is facing a class action lawsuit alleging that the Company made materially false and/or misleading statements and/or failed to disclose that defendants orchestrated a scheme to inflate Dentsply’s revenue and earnings by manipulating the Company's accounting for a distributor rebate program so that senior executives would be eligible for significant cash and stock-based incentive compensation. In order to facilitate this scheme, Dentsply and its executives made numerous false and misleading statements to investors during the class period. As a result of defendants’ misrepresentations, Dentsply’s common stock traded at artificially inflated prices during the class period.
If you incurred a loss on XRAY common stock purchased between June 9, 2021, and May 9, 2022, inclusive, this lawsuit is on your behalf. The lawsuit was filed in the United States District Court for the Southern District of Ohio, and our firm is reaching out to investors to discuss their legal rights.
If you wish to act as a representative of the shareholders harmed by this misconduct, you may ask the court to appoint you as lead plaintiff. A lead plaintiff directs the litigation and participates in important decisions, including whether to accept a settlement for the class in the action.
You only have until August 1, 2022 to apply to be lead plaintiff. The court will then evaluate the applicants and choose a lead plaintiff. You are not required to act as a lead plaintiff in order to participate in any recovery.